Evidence map›Paper›PMID 31650161›Full record

ArticleThe Journal of clinical endocrinology and metabolism2020

Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.

Cyrus V Desouza, Richard G Holcomb, Julio Rosenstock, Juan P Frias, Stanley H Hsia, Eric J Klein, Rong Zhou, Takuji Kohzuma, Vivian A Fonseca

Registry-linked trialOpen access · hybridAbstract readComparative StudyMulticenter Study
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02489773 (Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02489773 completednot on this map

Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study

TypeobservationalSponsorAsahi Kasei Therapeutics CorporationRan2015 to 2016Enrolled150ConditionsDiabetes
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Hyperglycemia inhibits AAA expansion: examining the role of lysyl oxidase.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine.The Journal of clinical endocrinology and metabolism · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Cyrus V DesouzaUniversity of Nebraska Medical Center, Omaha, Nebraska.
Richard G HolcombQuintiles Consulting, Inc., Rockville, Maryland.
Julio RosenstockDallas Diabetes Research Center at Medical City, Dallas, Texas.
Juan P FriasNational Research Institute, Los Angeles, California.
Stanley H HsiaNational Research Institute, Los Angeles, California.
Eric J KleinCapital Medical Center, Olympia, Washington.
Rong ZhouMedpace, Inc., Cincinnati, Ohio.
Takuji KohzumaAsahi Kasei Pharma, Tokyo, Japan.
Vivian A FonsecaTulane University Health Sciences Center, New Orleans, Louisiana 70112.
National Research Institute · USAsahi Kasei (Japan) · JPCapital University · USDallas Diabetes Research Center · USIQVIA (United States) · USMedpace (United States) · USTulane University · USUniversity of Nebraska Medical Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

contextIntermediate-term glycemic control metrics fulfill a need for measures beyond hemoglobin A1C.

objectiveCompare glycated albumin (GA), a 14-day blood glucose measure, with other glycemic indices.

design24-week prospective study of assay performance.

setting8 US clinics.

participantsSubjects with type 1 (n = 73) and type 2 diabetes (n = 77) undergoing changes to improve glycemic control (n = 98) or with stable diabetes therapy (n = 52).

interventionsGA, fructosamine, and A1C measured at prespecified intervals. Mean blood glucose (MBG) calculated using weekly self-monitored blood glucose profiles.

main outcome measuresPrimary: Pearson correlation between GA and fructosamine. Secondary: magnitude (Spearman correlation) and direction (Kendall correlation) of change of glycemic indices in the first 3 months after a change in diabetes management.

resultsGA was more concordant (60.8%) with changes in MBG than fructosamine (55.5%) or A1C (45.5%). Across all subjects and visits, the GA Pearson correlation with fructosamine was 0.920. Pearson correlations with A1C were 0.655 for GA and 0.515 for fructosamine (P < .001) and with MBG were 0.590 and 0.454, respectively (P < .001). At the individual subject level, Pearson correlations with both A1C and MBG were higher for GA than for fructosamine in 56% of subjects; only 4% of subjects had higher fructosamine correlations with A1C and MBG. GA had a higher Pearson correlation with A1C and MBG in 82% and 70% of subjects, respectively.

conclusionsCompared with fructosamine, GA correlates significantly better with both short-term MBG and long-term A1C and may be more useful than fructosamine in clinical situations requiring monitoring of intermediate-term glycemic control (NCT02489773).

Indexed as

Glycemic IndexBiomarkersBlood GlucoseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleFollow-Up StudiesFructosamineGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, AdvancedHumansHypoglycemic AgentsMaleMiddle AgedPrognosisBiomarkersBlood GlucoseFructosamineGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, Advancedhemoglobin A1c protein, humanHypoglycemic AgentsSerum Albumin

Identifiers

PMID31650161
PMCPMC7112979
OpenAlexW2981351708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.